High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing–remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent internation...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CNS drugs Jg. 36; H. 12; S. 1285 - 1299
Hauptverfasser:	Freeman, Léorah, Longbrake, Erin E., Coyle, Patricia K., Hendin, Barry, Vollmer, Timothy
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.12.2022 Springer Nature B.V
Schlagworte:	Alemtuzumab - therapeutic use Atrophy Cladribine Clinical outcomes Decision making FDA approval Humans Immunologic Factors - therapeutic use Inflammation Medicine Medicine & Public Health Monoclonal antibodies Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurology Neurosciences Patients Pharmacotherapy Psychiatry Psychopharmacology Review Review Article United States > US Europe
ISSN:	1172-7047, 1179-1934, 1179-1934
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!